Celltrion Accelerates Development of COVID-19 Antiviral Treatment and Aims to Launch Rapid Self-testing Kit

Celltrion completes first step of developing an antiviral treatment to fight COVID-19 and hopes to begin human clinical trials in the third quarter of 2020 Celltrion aims to launch the rapid self-testing diagnostic kit for COVID-19 this summer: the kit is designed to provide results within 15-20 min of self-testing Leveraging its world-class expertise in … [Read more…]

Applied DNA Leverages COVID-19 Vaccine Development and Proprietary Linear DNA Manufacturing Capability to Design a High Sensitivity Diagnostic Kit for Virus Detection

– Assay under development uses PCR-based detection of viral sequences that code for the Spike protein that is also the target of the Company’s vaccine candidate with Takis Biotech – – messenger RNA abundance for Spike in host cells should yield high sensitivity – STONY BROOK, N.Y.–(BUSINESS WIRE)–Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” … [Read more…]

Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

63 days from sequence selection to Phase 1 study dosing mRNA-1273 is Moderna’s 10th infectious disease vaccine to begin a clinical trial CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the first … [Read more…]

Applied DNA Sciences Updates on COVID-19 Collaboration with Takis Biotech, 4 Preclinical LinearDNA™ Vaccine Candidates Designed

– Applied DNA Expected to Enter Large-Scale Production of Candidates in March; Preclinical Testing in Animals by Takis Biotech Anticipated to Begin in Calendar Q2 2020– –Candidates Inspired by the Sequence of Viral Spike Protein; Designed to Prevent Entry of Coronavirus into Human Host’s Cells – STONY BROOK, N.Y. & ROME–(BUSINESS WIRE)–Applied DNA Sciences Inc. … [Read more…]

Moderna Announces Progress in Prophylactic Vaccines Modality with CMV Vaccine Phase 2 Study Data Now Expected in Third Quarter 2020 and Expands Investment in This Core Modality with Three New Development Candidates

Phase 2 CMV vaccine dose-confirmation study more than sixty percent enrolled mRNA-1189 to prevent infectious mononucleosis and Epstein-Barr virus (EBV) infection mRNA-1345 to prevent respiratory syncytial virus (RSV) disease in young children, with the intent to combine with mRNA-1653 to create a pediatric respiratory vaccine against RSV, hMPV and PIV3 mRNA-1273 to prevent novel coronavirus … [Read more…]

Halo Labs Provides Oregon Business Update Company Projects Record September Sales Orders in Oregon

Not for Distribution to U.S. Newswire Servicers or For Dissemination in the United States TORONTO–(BUSINESS WIRE)–Halo Labs Inc. (“Halo” or the “Company”) (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) announces that in September, its Oregon business unit (“ANM”) will have a record level of monthly sales orders totaling approximately $1.8 million (all figures are USD unless … [Read more…]

Columbia Care Completes Consolidation of Minority Interest in Illinois Operations

With 100% ownership, Company expects to complete buildout of vertically integrated operations, including its cultivation and manufacturing facility in Aurora in the fourth quarter and second dispensary location in the Chicagoland area once approved by state and city regulators Illinois projected to be a $2 billion market subsequent to implementation of adult use and expanded … [Read more…]